

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU et al.

Application Serial No.: 09/935,726

Filing Date: August 24, 2001

Title: Vascular Endothelial Growth Factor 2



Art Unit: 1647

Examiner: To be assigned

Atty. Dkt No.: PF112P3D1C1

**RESPONSE TO NOTICE TO FILE CORRECTED
APPLICATION PAPERS AND NOTICE TO COMPLY**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice to File Corrected Application Papers (Formalities Letter Confirmation No. 3533) mailed on December 4, 2001 requesting substitute drawings, and sequence listing in compliance with §§ 1.821-1.825, Applicants submit herewith: (a) a Fee Transmittal; (b) a Substitute Sequence Listing in paper (pages 1-20) and computer-readable (diskette) forms; (c) Statement Under 37 C.F.R. §§ 1.825(a)-(b); (d) 47 Sheets of Substitute Drawings containing Figures 1A-29, (e) Information Disclosure Statement, Form PTO/SB/08, references AA-FO and 13 Statutory Declarations and accompanying exhibits; and (f) a Copy of Notice to File Corrected Application Papers. Please amend the application as follows.

#6

In the Sequence Listing

Please replace the Sequence Listing (pages 133-156) with the Substitute Sequence Listing (pages 1-20) submitted herewith. Please also enter the CRF form of the Sequence Listing submitted herewith.

Remarks

The Substitute Sequence Listing has been submitted to correct typographical errors in the sequence and numeric identifiers of SEQ ID NO:3. Specifically, SEQ ID NO:3 has been amended to delete the nucleotide "t" at position 1508. Additionally, the base pair total for SEQ ID NO:3 has been amended to recite "1525" where it previously recited "1526."

Support for the amendment to SEQ ID NO:3 can first be found, for example, in Figure 2D. The additional nucleotide "t" at position 1508 of SEQ ID NO:3 differs from the disclosure of Figure 2D, which does not have a nucleotide "T" at position 1508. Furthermore, SEQ ID NO:3, having 1526bp, and Figure 2D having 1525bp, differ in length by one nucleotide.

Additional support for the amendment to SEQ ID NO:3 can be found in the specification, for example, on page 84, lines 21 to 23. Here, the specification indicates that an antisense primer anneals with its 5' end at position 1259 bp of the truncated VEGF-2 cDNA, whereby the nucleotide sequence of the truncated VEGF-2 cDNA is shown in SEQ ID NO:3 (see figure legend of Figure 2A-D, page 6). The specification further indicates that the 1259 bp position is 266 bp before the last nucleotide of the cDNA. Thus, by adding these two figures the length of SEQ ID NO:3 is figured to be 1525 bp (i.e. 1259 +

266 = 1525). Therefore, one of skill in the art would deduce that Figure 2D has the correct length of 1525 bp and that the length in SEQ ID NO:3 is not correct.

Substitute drawings of Figures 1A-29 have been provided in accordance with 37 C.F.R. § 1.84(g).

The amendments are fully supported by the application and claims as originally filed. Thus, no new matter has been added by way of amendment. Entry of the above amendment is therefore respectfully solicited.

Conclusion


Applicants respectfully request that the above-made amendments and remarks be entered and made of record in the file history of the instant application. Applicants believe that this application is in condition for substantive examination. If in the opinion of the Examiner, a telephone conference would expedite prosecution, the undersigned can be reached at the telephone number indicated below.

If there are any fees due in connection with the filing of this paper, please charge the fees to Deposit Account No. 08-3425.

Respectfully submitted,

Dated:

Jan 25, 2002


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosures
MMW/AKR/lcc

TRANSMITTAL

for FY 2002

Student fees are subject to annual revision.

Application Number	HU et al.
Filing Date	August 24, 2001
First Named Inventor	09/935,726
Examiner Name	Unassigned
Group Art Unit	1647
Attorney Docket Number	PF112P3D1C1

\$ 0.00

FEE CALCULATION (continued)

- Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/935,726	08/24/2001	Jing-Shan Hu	PF112P3D1C1

CONFIRMATION NO. 3533

22195
HUMAN GENOME SCIENCES INC
9410 KEY WEST AVENUE
ROCKVILLE, MD 20850

FORMALITIES LETTER



OC000000007152343

Date Mailed: 12/04/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

